The feasibility study of accelated infliximab infusion from initial administratio
Phase 2
Recruiting
- Conditions
- patient in whom infliximab is indicated(rheumatoid arthritis, Crohn's disease, Ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis)
- Registration Number
- JPRN-UMIN000015297
- Lead Sponsor
- Chiba University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 54
Inclusion Criteria
Not provided
Exclusion Criteria
1)active serious infection 2)active tuberuculosis infection 3)allergy and/or hypersensitivity for mouse-derived protein 4)demyelinating disease(MS) 5)congestive heart failure 6)pregnant, nursing or likelihood of pregnancy woman 7)unable to birth control during and after 6 months from the latest infliximab administration 8)Not suitable for participating in the study for any other reason
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The incidence of infusion reaction with 60min infliximab accelated infusion
- Secondary Outcome Measures
Name Time Method discontinuous rate due to infusion reaction success rate of rescue by usual 2hrs infusion after occurrence of infusion reaction evaluation of premedication